LBRX
Live News • Jul 01
LB Pharmaceuticals Names Zergebel to Lead Clinical Operations as LB-102 Trials Advance LB Pharmaceuticals has appointed Christopher Zergebel as Senior Vice President, Clinical Operations, bringing over 25 years of global development operations experience to oversee execution of its LB-102 clinical programs.
Zergebel will support multiple trials for LB-102, including Phase 3 and Phase 2 studies in schizophrenia and bipolar depression, and a Phase 2 trial in adjunctive major depressive disorder that is expected to begin early next year.
LB Pharmaceuticals’ stock trades at US$32.45, with the share price up 58.8% year to date.
This hire concentrates more operational experience around LB-102, which is central to LB Pharmaceuticals’ pipeline. The key question for investors is whether added clinical operations depth helps the company manage simultaneous late-stage trials and timelines effectively, since any delays or execution issues around LB-102 would directly affect how the story develops from here. Announcement • Jun 30
LB Pharmaceuticals Inc Announces Appointment of Christopher Zergebel to Senior Vice President, Clinical Operations LB Pharmaceuticals Inc. announced the appointment of Christopher Zergebel as Senior Vice President, Clinical Operations. Mr. Zergebel, a seasoned biotechnology executive with more than 25 years of global development operations experience, brought deep expertise in growing and leading cross-functional teams including clinical operations, data management, and project and portfolio management. Prior to joining LB Pharmaceuticals, Mr. Zergebel served as Vice President, Development Operations at Cellectis Biologics, where he led global clinical development strategy and operations from early stage through post approval trials. Prior to Cellectis, Mr. Zergebel held senior leadership roles where he was responsible for establishing and optimizing development operations functions, overseeing R&D budgets, and successfully executing clinical programs. He has successfully led clinical operations for programs resulting in regulatory submissions and approvals and has built global project management and clinical infrastructure capabilities. Mr. Zergebel holds a B.A. in Biology from Boston University. Announcement • Jun 11
LB Pharmaceuticals Inc Announces Resignation of Anna Eramo as Chief Medical Officer, Effective June 15, 2026 On June 16, 2026, Anna Eramo, M.D., for personal reasons will transition to a role of advisor to LB Pharmaceuticals Inc. On June 8, 2026, she resigned from her position as Chief Medical Officer of the Company effective June 15, 2026 (the “ Separation Date”). She will continue to provide consulting services in a full-time capacity to the Company through September 15, 2026. Dr. Eramo’s departure is not related to the Company’s clinical program operations or practices, and the Company does not expect her departure to have a material impact on the Company’s clinical development activities or previously disclosed clinical milestones. A search is underway for her replacement, and the Company has experienced clinical development and operations teams who will continue to oversee the execution of the ongoing clinical trials. 
